Cymat Technologies Ltd

As of April 30, 2026, Cymat Technologies Ltd carries a market capitalization of 7.53M, placing it among publicly traded companies globally. Its enterprise value stands at 14.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Cymat Technologies Ltd has 100.37M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 3.49, and the price-to-book ratio stands at -1.18.

These figures are as of April 30, 2026. The EV/Sales ratio of 7.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.18M versus a market cap of 7.53M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Cymat Technologies Ltd maintains a current ratio of 0.22, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -106.61, indicating conservative leverage, while an interest coverage ratio of -1.78 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -162.57, reflecting losses generated across the asset base. The company generates approximately 176,790.18 in revenue per employee across its workforce of 11.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.67 indicates how many times Cymat Technologies Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Cymat Technologies Ltd's stock has declined approximately 16.67% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.09.

Over the twelve months ended April 30, 2026, Cymat Technologies Ltd generated 1.94M in revenue and converted that into -4.94M in net income, yielding earnings per share of -0.05. EBITDA reached -2.61M, while operating income came in at -3.17M.

As of April 30, 2026, Cymat Technologies Ltd holds 140,852.00 in cash and equivalents against 6.79M in total debt, resulting in a net debt position of 5.50M. Total book value stands at -6.37M, with working capital of -6.42M providing operational flexibility.

Cymat Technologies Ltd produced -2.65M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -86,270.00 in capital expenditures, free cash flow totaled -2.74M - equivalent to -0.03 per share.

Over the twelve months ended April 30, 2026, Cymat Technologies Ltd posted a gross margin of -0.14, reflecting its pricing power and cost economics. The operating margin of -163.19 and net profit margin of -253.87 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -40.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -37.88, meaning Cymat Technologies Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cymat Technologies Ltd's most recent stock split took place on June 25, 2014 with a 10:1 split ratio.

As of April 30, 2026, Cymat Technologies Ltd has an Altman Z-Score of -50.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.